Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427349 · ClinicalTrials.gov registry record · Phase 2
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00427349 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 46 participants.
The verdict
NCT00427349, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.
Interventions
- DRUG AMG 706
- DRUG octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-11-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427349
The ClinicalTrials.gov registry entry for NCT00427349 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG 706 is the first listed.
NCT00427349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427349 about?
NCT00427349 is a clinical study titled "AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors". RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumor...
What is the current status of trial NCT00427349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-11-07. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00427349?
The interventions under investigation include: AMG 706 (DRUG), octreotide (DRUG).
Who is sponsoring clinical trial NCT00427349?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.